Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Transplantation Conditioning | 33 | 2022 | 1571 | 2.180 |
Why?
|
Cyclophosphamide | 20 | 2021 | 2193 | 1.750 |
Why?
|
Hematopoietic Stem Cell Transplantation | 37 | 2022 | 5145 | 1.680 |
Why?
|
Graft vs Host Disease | 28 | 2021 | 2817 | 1.630 |
Why?
|
Bone Marrow Transplantation | 25 | 2021 | 2784 | 1.610 |
Why?
|
Hematologic Neoplasms | 20 | 2019 | 1700 | 1.460 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 9 | 2017 | 278 | 1.200 |
Why?
|
Bone Neoplasms | 9 | 2022 | 2583 | 1.180 |
Why?
|
Chondrosarcoma | 4 | 2021 | 310 | 1.150 |
Why?
|
Tissue Donors | 12 | 2020 | 2156 | 1.110 |
Why?
|
Osteoblastoma | 2 | 2021 | 27 | 1.050 |
Why?
|
Osteoma, Osteoid | 2 | 2021 | 78 | 1.020 |
Why?
|
Busulfan | 9 | 2021 | 272 | 0.710 |
Why?
|
HLA Antigens | 12 | 2021 | 1552 | 0.700 |
Why?
|
Hematopoietic Stem Cell Mobilization | 7 | 2017 | 221 | 0.670 |
Why?
|
Antigens, CD34 | 5 | 2017 | 671 | 0.670 |
Why?
|
Soft Tissue Neoplasms | 3 | 2021 | 1359 | 0.570 |
Why?
|
Immunosuppressive Agents | 13 | 2017 | 4204 | 0.560 |
Why?
|
Hospitals, Special | 1 | 2015 | 112 | 0.540 |
Why?
|
Hematologic Diseases | 2 | 2019 | 494 | 0.530 |
Why?
|
Haplotypes | 6 | 2017 | 2883 | 0.500 |
Why?
|
Transplantation, Homologous | 24 | 2020 | 4846 | 0.490 |
Why?
|
Antilymphocyte Serum | 3 | 2021 | 519 | 0.490 |
Why?
|
Vidarabine | 8 | 2021 | 349 | 0.470 |
Why?
|
Histocompatibility Testing | 9 | 2017 | 803 | 0.410 |
Why?
|
Lymphocyte Depletion | 4 | 2012 | 636 | 0.390 |
Why?
|
Chondroma | 2 | 2021 | 60 | 0.390 |
Why?
|
Lipoma | 1 | 2012 | 335 | 0.390 |
Why?
|
Cord Blood Stem Cell Transplantation | 3 | 2021 | 323 | 0.390 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2012 | 380 | 0.380 |
Why?
|
Vidarabine Phosphate | 4 | 2014 | 11 | 0.380 |
Why?
|
Fever | 2 | 2014 | 1591 | 0.380 |
Why?
|
Liposarcoma | 1 | 2012 | 316 | 0.380 |
Why?
|
Myeloablative Agonists | 6 | 2016 | 225 | 0.350 |
Why?
|
Tissue and Organ Harvesting | 4 | 2020 | 363 | 0.340 |
Why?
|
Histocompatibility | 4 | 2016 | 360 | 0.330 |
Why?
|
Guideline Adherence | 2 | 2015 | 2331 | 0.330 |
Why?
|
Fetal Blood | 3 | 2021 | 1337 | 0.320 |
Why?
|
Blood Component Removal | 2 | 2012 | 117 | 0.300 |
Why?
|
Donor Selection | 4 | 2019 | 189 | 0.290 |
Why?
|
Bone Marrow | 5 | 2022 | 2959 | 0.280 |
Why?
|
Granulocyte Colony-Stimulating Factor | 5 | 2016 | 639 | 0.270 |
Why?
|
Leukemia, Myeloid, Acute | 6 | 2021 | 3333 | 0.270 |
Why?
|
Adult | 59 | 2022 | 212408 | 0.250 |
Why?
|
Adolescent | 40 | 2022 | 85136 | 0.240 |
Why?
|
Arthroplasty, Replacement, Ankle | 1 | 2022 | 22 | 0.230 |
Why?
|
Health Care Surveys | 1 | 2010 | 2511 | 0.220 |
Why?
|
Young Adult | 29 | 2021 | 56237 | 0.210 |
Why?
|
Enchondromatosis | 1 | 2021 | 15 | 0.210 |
Why?
|
Immunotherapy, Adoptive | 2 | 2022 | 1037 | 0.210 |
Why?
|
Excitatory Amino Acid Agonists | 1 | 2001 | 157 | 0.210 |
Why?
|
Gene Rearrangement | 3 | 2021 | 1205 | 0.200 |
Why?
|
T-Lymphocytes | 6 | 2017 | 10372 | 0.200 |
Why?
|
Middle Aged | 55 | 2022 | 214874 | 0.200 |
Why?
|
N-Methylaspartate | 1 | 2001 | 223 | 0.200 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 298 | 0.200 |
Why?
|
Humans | 90 | 2022 | 716923 | 0.200 |
Why?
|
Erythroid Precursor Cells | 1 | 2001 | 226 | 0.190 |
Why?
|
Transplantation Chimera | 4 | 2015 | 622 | 0.190 |
Why?
|
Chondromatosis, Synovial | 1 | 2019 | 14 | 0.190 |
Why?
|
Aged | 41 | 2022 | 162670 | 0.190 |
Why?
|
Receptors, Dopamine D1 | 1 | 2001 | 297 | 0.180 |
Why?
|
Male | 63 | 2022 | 351000 | 0.180 |
Why?
|
Activin Receptors, Type II | 1 | 2019 | 110 | 0.180 |
Why?
|
Pyramidal Cells | 1 | 2001 | 363 | 0.170 |
Why?
|
Disease-Free Survival | 11 | 2016 | 7039 | 0.170 |
Why?
|
Neurotoxicity Syndromes | 1 | 2022 | 267 | 0.170 |
Why?
|
Child | 24 | 2022 | 74422 | 0.160 |
Why?
|
Female | 60 | 2022 | 377705 | 0.160 |
Why?
|
Haploidy | 2 | 2016 | 155 | 0.160 |
Why?
|
Killer Cells, Natural | 2 | 2017 | 2183 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-fos | 1 | 2019 | 586 | 0.150 |
Why?
|
Achilles Tendon | 1 | 2018 | 130 | 0.150 |
Why?
|
Hematopoietic Stem Cells | 3 | 2017 | 3447 | 0.150 |
Why?
|
Giant Cell Tumor of Bone | 1 | 2017 | 123 | 0.150 |
Why?
|
Tendinopathy | 1 | 2018 | 129 | 0.150 |
Why?
|
Retrospective Studies | 20 | 2022 | 72619 | 0.150 |
Why?
|
Radioimmunotherapy | 1 | 2015 | 73 | 0.140 |
Why?
|
Living Donors | 2 | 2010 | 574 | 0.140 |
Why?
|
Fibronectins | 1 | 2019 | 726 | 0.140 |
Why?
|
Hodgkin Disease | 3 | 2011 | 1442 | 0.140 |
Why?
|
Osteoarthritis | 1 | 2022 | 966 | 0.140 |
Why?
|
Whole-Body Irradiation | 4 | 2021 | 456 | 0.140 |
Why?
|
Erdheim-Chester Disease | 1 | 2014 | 12 | 0.140 |
Why?
|
Cell Separation | 1 | 2001 | 1826 | 0.130 |
Why?
|
Biopsy, Needle | 1 | 2020 | 1681 | 0.130 |
Why?
|
Melphalan | 1 | 2015 | 383 | 0.130 |
Why?
|
Recurrence | 10 | 2014 | 8250 | 0.130 |
Why?
|
Biomarkers, Pharmacological | 2 | 2013 | 172 | 0.130 |
Why?
|
Isoantibodies | 1 | 2018 | 668 | 0.130 |
Why?
|
Lymphopoiesis | 1 | 2014 | 137 | 0.130 |
Why?
|
Central Nervous System Neoplasms | 1 | 2022 | 869 | 0.120 |
Why?
|
Radiography, Thoracic | 1 | 2020 | 1346 | 0.120 |
Why?
|
Graft Survival | 5 | 2015 | 3764 | 0.120 |
Why?
|
Mesenchymal Stem Cell Transplantation | 1 | 2018 | 483 | 0.120 |
Why?
|
Bacteremia | 1 | 2020 | 972 | 0.120 |
Why?
|
Respiratory Insufficiency | 1 | 2021 | 1145 | 0.120 |
Why?
|
Filgrastim | 4 | 2015 | 134 | 0.120 |
Why?
|
Lymphoma | 1 | 2022 | 1889 | 0.120 |
Why?
|
Area Under Curve | 3 | 2013 | 1692 | 0.120 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2022 | 2504 | 0.120 |
Why?
|
Accreditation | 1 | 2015 | 447 | 0.110 |
Why?
|
Foot Diseases | 1 | 2013 | 145 | 0.110 |
Why?
|
Survival Rate | 8 | 2017 | 13243 | 0.110 |
Why?
|
Point-of-Care Systems | 1 | 2001 | 1125 | 0.110 |
Why?
|
Treatment Outcome | 18 | 2022 | 62172 | 0.100 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2019 | 2659 | 0.100 |
Why?
|
GTP Phosphohydrolases | 1 | 2014 | 514 | 0.100 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2011 | 11325 | 0.100 |
Why?
|
Synovitis, Pigmented Villonodular | 1 | 2010 | 36 | 0.100 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2014 | 651 | 0.100 |
Why?
|
Bone Marrow Cells | 1 | 2019 | 2591 | 0.100 |
Why?
|
Prefrontal Cortex | 1 | 2001 | 2060 | 0.100 |
Why?
|
Blood Donors | 1 | 2012 | 355 | 0.100 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2017 | 645 | 0.100 |
Why?
|
Osteitis | 1 | 2009 | 24 | 0.100 |
Why?
|
Pain | 5 | 2022 | 4700 | 0.090 |
Why?
|
Foot | 1 | 2013 | 509 | 0.090 |
Why?
|
Fanconi Anemia | 1 | 2012 | 322 | 0.090 |
Why?
|
Graft Rejection | 5 | 2018 | 4417 | 0.090 |
Why?
|
Salvage Therapy | 1 | 2016 | 1309 | 0.090 |
Why?
|
Lymphocyte Transfusion | 2 | 2016 | 239 | 0.090 |
Why?
|
Sarcoma | 1 | 2020 | 1881 | 0.090 |
Why?
|
Physician Executives | 1 | 2010 | 136 | 0.090 |
Why?
|
Hospital Bed Capacity | 1 | 2010 | 199 | 0.090 |
Why?
|
Pilot Projects | 4 | 2019 | 8073 | 0.090 |
Why?
|
Immunoconjugates | 1 | 2015 | 838 | 0.090 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2011 | 1394 | 0.090 |
Why?
|
Mixed Tumor, Malignant | 1 | 2008 | 16 | 0.090 |
Why?
|
Liposarcoma, Myxoid | 1 | 2008 | 63 | 0.090 |
Why?
|
Leukemia, Myeloid | 3 | 2014 | 730 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2022 | 8927 | 0.080 |
Why?
|
Blood Specimen Collection | 1 | 2009 | 247 | 0.080 |
Why?
|
Fetal Proteins | 1 | 2008 | 94 | 0.080 |
Why?
|
Myoepithelioma | 1 | 2008 | 44 | 0.080 |
Why?
|
Killer Cells, Lymphokine-Activated | 1 | 2007 | 44 | 0.080 |
Why?
|
Gene Amplification | 1 | 2012 | 1077 | 0.080 |
Why?
|
Hemoglobinuria, Paroxysmal | 1 | 2008 | 100 | 0.080 |
Why?
|
Follow-Up Studies | 7 | 2020 | 39257 | 0.080 |
Why?
|
Muscle Neoplasms | 1 | 2008 | 142 | 0.080 |
Why?
|
Histones | 1 | 2017 | 2588 | 0.080 |
Why?
|
Models, Biological | 3 | 2014 | 9885 | 0.080 |
Why?
|
Stem Cell Transplantation | 1 | 2016 | 1648 | 0.080 |
Why?
|
Magnetic Resonance Imaging | 7 | 2022 | 34530 | 0.070 |
Why?
|
Child, Preschool | 10 | 2022 | 41197 | 0.070 |
Why?
|
Kidney Failure, Chronic | 1 | 2019 | 2567 | 0.070 |
Why?
|
Incidence | 8 | 2021 | 20648 | 0.070 |
Why?
|
Joint Diseases | 1 | 2010 | 457 | 0.070 |
Why?
|
Social Class | 1 | 2015 | 1978 | 0.070 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2007 | 326 | 0.070 |
Why?
|
Myelodysplastic Syndromes | 3 | 2016 | 1265 | 0.070 |
Why?
|
Muscle, Skeletal | 2 | 2013 | 4993 | 0.070 |
Why?
|
T-Box Domain Proteins | 1 | 2008 | 473 | 0.070 |
Why?
|
Bone Marrow Purging | 2 | 2002 | 112 | 0.070 |
Why?
|
Combined Modality Therapy | 4 | 2012 | 8913 | 0.070 |
Why?
|
Fatigue | 1 | 2012 | 1457 | 0.070 |
Why?
|
Hemangioma | 1 | 2010 | 738 | 0.070 |
Why?
|
Conflict of Interest | 1 | 2010 | 561 | 0.070 |
Why?
|
Acute Disease | 5 | 2021 | 7165 | 0.070 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 904 | 0.060 |
Why?
|
Chordoma | 1 | 2008 | 384 | 0.060 |
Why?
|
Adoptive Transfer | 1 | 2007 | 873 | 0.060 |
Why?
|
Kidney Transplantation | 1 | 2019 | 4148 | 0.060 |
Why?
|
Informed Consent | 1 | 2010 | 957 | 0.060 |
Why?
|
Immune Tolerance | 1 | 2012 | 2331 | 0.060 |
Why?
|
Remission Induction | 4 | 2013 | 2385 | 0.060 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2017 | 3057 | 0.060 |
Why?
|
Blood Cell Count | 2 | 2015 | 419 | 0.060 |
Why?
|
Transplantation, Autologous | 4 | 2018 | 2080 | 0.060 |
Why?
|
Cell Count | 2 | 2019 | 1916 | 0.060 |
Why?
|
Hypoglycemia | 1 | 2009 | 811 | 0.060 |
Why?
|
Family | 2 | 2011 | 3105 | 0.060 |
Why?
|
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 1 | 2001 | 57 | 0.050 |
Why?
|
Aged, 80 and over | 5 | 2021 | 58457 | 0.050 |
Why?
|
Knee Joint | 1 | 2010 | 1575 | 0.050 |
Why?
|
Neoplasm, Residual | 2 | 2017 | 992 | 0.050 |
Why?
|
State Medicine | 1 | 2022 | 206 | 0.050 |
Why?
|
Chronic Disease | 5 | 2021 | 9038 | 0.050 |
Why?
|
Fluorometry | 1 | 2001 | 115 | 0.050 |
Why?
|
Arthrodesis | 1 | 2022 | 189 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2017 | 6748 | 0.050 |
Why?
|
Hematopoiesis | 2 | 2021 | 2018 | 0.050 |
Why?
|
Nuclear Family | 1 | 2002 | 312 | 0.050 |
Why?
|
Chimerism | 1 | 2021 | 150 | 0.050 |
Why?
|
Mutation | 4 | 2020 | 29440 | 0.050 |
Why?
|
Proportional Hazards Models | 2 | 2015 | 12412 | 0.050 |
Why?
|
Diagnosis, Differential | 4 | 2022 | 13269 | 0.050 |
Why?
|
Lymphoma, B-Cell | 1 | 2007 | 938 | 0.050 |
Why?
|
Ankle | 1 | 2022 | 271 | 0.050 |
Why?
|
Hyperglycemia | 1 | 2009 | 1359 | 0.050 |
Why?
|
Consensus | 2 | 2019 | 2737 | 0.050 |
Why?
|
Interleukin-2 | 1 | 2007 | 1923 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 3 | 2020 | 20416 | 0.050 |
Why?
|
Antigens, CD19 | 1 | 2022 | 353 | 0.050 |
Why?
|
United States | 4 | 2021 | 67744 | 0.050 |
Why?
|
Switzerland | 1 | 2019 | 275 | 0.050 |
Why?
|
Oncogene Fusion | 1 | 2019 | 110 | 0.040 |
Why?
|
Ankle Joint | 1 | 2022 | 374 | 0.040 |
Why?
|
Mycophenolic Acid | 2 | 2013 | 344 | 0.040 |
Why?
|
England | 1 | 2019 | 516 | 0.040 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2001 | 524 | 0.040 |
Why?
|
Patch-Clamp Techniques | 1 | 2001 | 979 | 0.040 |
Why?
|
Dopamine Agonists | 1 | 2001 | 353 | 0.040 |
Why?
|
Injections, Intravenous | 2 | 2011 | 1479 | 0.040 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2011 | 4382 | 0.040 |
Why?
|
Hyperplasia | 1 | 2021 | 1170 | 0.040 |
Why?
|
Ciprofloxacin | 1 | 2020 | 314 | 0.040 |
Why?
|
London | 1 | 2018 | 236 | 0.040 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2019 | 195 | 0.040 |
Why?
|
Electrophysiology | 1 | 2001 | 1323 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2011 | 4272 | 0.040 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 260 | 0.040 |
Why?
|
Recombinant Proteins | 3 | 2014 | 6852 | 0.040 |
Why?
|
Arthralgia | 1 | 2022 | 466 | 0.040 |
Why?
|
Postoperative Complications | 3 | 2019 | 15116 | 0.040 |
Why?
|
Immunohistochemistry | 3 | 2019 | 11756 | 0.040 |
Why?
|
Calcium Channels | 1 | 2001 | 656 | 0.040 |
Why?
|
Membrane Proteins | 1 | 2014 | 8103 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2020 | 12574 | 0.040 |
Why?
|
Nitriles | 1 | 2021 | 950 | 0.040 |
Why?
|
Antineoplastic Agents | 4 | 2012 | 13730 | 0.040 |
Why?
|
Receptors, KIR | 1 | 2016 | 121 | 0.040 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2017 | 255 | 0.040 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2017 | 314 | 0.040 |
Why?
|
Cyclosporine | 1 | 1998 | 826 | 0.040 |
Why?
|
Blood Transfusion | 1 | 2001 | 1257 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2018 | 632 | 0.030 |
Why?
|
Time Factors | 5 | 2017 | 40979 | 0.030 |
Why?
|
Extremities | 1 | 2020 | 874 | 0.030 |
Why?
|
Survival Analysis | 4 | 2014 | 10528 | 0.030 |
Why?
|
Bayes Theorem | 2 | 2014 | 2050 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2020 | 629 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2017 | 5034 | 0.030 |
Why?
|
Cause of Death | 2 | 2021 | 3590 | 0.030 |
Why?
|
Spine | 1 | 2021 | 1114 | 0.030 |
Why?
|
Heel | 1 | 2013 | 37 | 0.030 |
Why?
|
Half-Life | 1 | 2014 | 682 | 0.030 |
Why?
|
Injections, Subcutaneous | 1 | 2014 | 687 | 0.030 |
Why?
|
Disease Progression | 3 | 2017 | 13287 | 0.030 |
Why?
|
Anesthesia | 2 | 2015 | 1515 | 0.030 |
Why?
|
Convalescence | 1 | 2012 | 107 | 0.030 |
Why?
|
Lymphocyte Count | 1 | 2014 | 812 | 0.030 |
Why?
|
Decision Trees | 1 | 2014 | 523 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2021 | 1743 | 0.030 |
Why?
|
Prospective Studies | 4 | 2019 | 51252 | 0.030 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2017 | 835 | 0.030 |
Why?
|
Risk Factors | 6 | 2014 | 70808 | 0.030 |
Why?
|
Lymphocytes | 1 | 2019 | 2745 | 0.030 |
Why?
|
Pyrazoles | 1 | 2021 | 1968 | 0.030 |
Why?
|
Antigens, Surface | 1 | 2015 | 1850 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2015 | 1902 | 0.030 |
Why?
|
Bone and Bones | 1 | 2021 | 2576 | 0.020 |
Why?
|
Transplantation Immunology | 1 | 2012 | 584 | 0.020 |
Why?
|
Antibodies, Monoclonal | 2 | 2015 | 9594 | 0.020 |
Why?
|
Histocytochemistry | 1 | 2011 | 759 | 0.020 |
Why?
|
Siblings | 1 | 2014 | 819 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2001 | 6122 | 0.020 |
Why?
|
Cytomegalovirus Infections | 1 | 2015 | 757 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 15245 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2001 | 8592 | 0.020 |
Why?
|
Syncope | 1 | 2012 | 434 | 0.020 |
Why?
|
Pyrimidines | 1 | 2021 | 2962 | 0.020 |
Why?
|
Europe | 1 | 2015 | 3330 | 0.020 |
Why?
|
Exanthema | 1 | 2012 | 460 | 0.020 |
Why?
|
Glutathione Transferase | 1 | 2010 | 615 | 0.020 |
Why?
|
Comparative Effectiveness Research | 1 | 2014 | 679 | 0.020 |
Why?
|
Myeloproliferative Disorders | 1 | 2014 | 607 | 0.020 |
Why?
|
Spermatogonia | 1 | 2008 | 35 | 0.020 |
Why?
|
Prognosis | 4 | 2017 | 29161 | 0.020 |
Why?
|
Hemangioblastoma | 1 | 2008 | 69 | 0.020 |
Why?
|
Gene Expression | 2 | 2014 | 8001 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2014 | 1733 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2017 | 19513 | 0.020 |
Why?
|
Blood Component Transfusion | 1 | 2008 | 126 | 0.020 |
Why?
|
International Cooperation | 1 | 2014 | 1417 | 0.020 |
Why?
|
Leukemia | 1 | 2015 | 1528 | 0.020 |
Why?
|
Reoperation | 1 | 2017 | 4181 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2017 | 6284 | 0.020 |
Why?
|
Infant | 3 | 2010 | 34567 | 0.020 |
Why?
|
Synovial Membrane | 1 | 2010 | 498 | 0.020 |
Why?
|
Leukapheresis | 1 | 2007 | 126 | 0.020 |
Why?
|
Nonlinear Dynamics | 1 | 2010 | 497 | 0.020 |
Why?
|
Neoplasms | 2 | 2014 | 20549 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2017 | 4915 | 0.020 |
Why?
|
Body Mass Index | 2 | 2015 | 12514 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2016 | 15981 | 0.020 |
Why?
|
Income | 1 | 2015 | 1805 | 0.020 |
Why?
|
Body Weight | 1 | 2017 | 4689 | 0.020 |
Why?
|
Cell Lineage | 1 | 2015 | 2615 | 0.020 |
Why?
|
Algorithms | 2 | 2011 | 13698 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2020 | 11179 | 0.020 |
Why?
|
Multiple Myeloma | 1 | 2003 | 5174 | 0.020 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2007 | 211 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2010 | 2299 | 0.020 |
Why?
|
Tacrolimus | 1 | 2008 | 714 | 0.020 |
Why?
|
Diphosphonates | 1 | 2009 | 629 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2012 | 1160 | 0.020 |
Why?
|
Rats | 1 | 2001 | 25068 | 0.020 |
Why?
|
Virus Activation | 1 | 2006 | 328 | 0.020 |
Why?
|
Immunotherapy | 1 | 2000 | 4128 | 0.020 |
Why?
|
Chromatography, Liquid | 1 | 2008 | 969 | 0.020 |
Why?
|
Proteomics | 1 | 2017 | 3264 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2010 | 935 | 0.020 |
Why?
|
Ambulatory Care Facilities | 1 | 2010 | 885 | 0.020 |
Why?
|
Receptors, IgG | 1 | 2007 | 609 | 0.020 |
Why?
|
Cohort Studies | 3 | 2014 | 39911 | 0.010 |
Why?
|
Risk | 1 | 2016 | 9770 | 0.010 |
Why?
|
Sex Factors | 1 | 2017 | 10658 | 0.010 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2008 | 476 | 0.010 |
Why?
|
Administration, Oral | 1 | 2010 | 3968 | 0.010 |
Why?
|
Multivariate Analysis | 2 | 2010 | 12476 | 0.010 |
Why?
|
Amino Acid Substitution | 1 | 2007 | 1834 | 0.010 |
Why?
|
Testicular Neoplasms | 1 | 2008 | 767 | 0.010 |
Why?
|
Lung | 1 | 2020 | 9782 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2020 | 7095 | 0.010 |
Why?
|
Baltimore | 1 | 2001 | 234 | 0.010 |
Why?
|
Postoperative Care | 1 | 2008 | 1512 | 0.010 |
Why?
|
Health Expenditures | 1 | 2014 | 2274 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2014 | 5259 | 0.010 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2006 | 557 | 0.010 |
Why?
|
Animals | 3 | 2015 | 170675 | 0.010 |
Why?
|
Mass Spectrometry | 1 | 2008 | 2247 | 0.010 |
Why?
|
Health Care Costs | 1 | 2014 | 3172 | 0.010 |
Why?
|
Herpesvirus 4, Human | 1 | 2006 | 1257 | 0.010 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2009 | 2265 | 0.010 |
Why?
|
Leukocyte Count | 1 | 2002 | 1665 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2014 | 9561 | 0.010 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2000 | 712 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2015 | 18301 | 0.010 |
Why?
|
Computer Simulation | 1 | 2010 | 6098 | 0.010 |
Why?
|
Antigens, CD | 1 | 2007 | 4154 | 0.010 |
Why?
|
Genotype | 1 | 2010 | 12924 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2006 | 6534 | 0.010 |
Why?
|
Blood Glucose | 1 | 2009 | 6296 | 0.010 |
Why?
|
Quality of Life | 1 | 2014 | 11749 | 0.010 |
Why?
|
Hospitalization | 1 | 2012 | 9773 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2010 | 12420 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2008 | 6299 | 0.010 |
Why?
|
Comorbidity | 1 | 2006 | 10452 | 0.010 |
Why?
|
Phenotype | 1 | 2008 | 16395 | 0.010 |
Why?
|
Obesity | 1 | 2012 | 12256 | 0.010 |
Why?
|
Neutrophils | 1 | 2002 | 3798 | 0.010 |
Why?
|
Mice | 1 | 2015 | 80995 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2001 | 13621 | 0.000 |
Why?
|
Age Factors | 1 | 2003 | 18787 | 0.000 |
Why?
|